Theriva Biologics (TOVX) Change in Account Payables (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Change in Account Payables of -$397000.0 for Q1 2026, up 9.77% year-over-year from -$361656.3 in Q1 2025, and down 289.95% quarter-over-quarter from $209000.0 in Q4 2025.
Theriva Biologics (TOVX) Change in Account Payables (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Change in Account Payables for 17 consecutive years, with -$397000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 9.77% year-over-year to -$397000.0; the TTM figure through Mar 2026 stood at $112000.0 (up 188.19% YoY), while the FY2025 annual figure was $69000.0, down 43.9% from the prior year.
- Change in Account Payables declined to -$397000.0 in Q1 2026 per TOVX's latest filing, from $209000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $369000.0 in Q2 2024 and bottomed at -$440000.0 in Q1 2023.
- Historically, Change in Account Payables has averaged -$43941.2 across 5 years, with a median of $13000.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables slumped 3484.62% — and 2024, when it soared 273.49%.
- Theriva Biologics' Change in Account Payables stood at $119000.0 in 2022, then plunged by 169.75% to -$83000.0 in 2023, then jumped by 273.49% to $144000.0 in 2024, then soared by 45.14% to $209000.0 in 2025, then slumped by 289.95% to -$397000.0 in 2026.
- Business Quant data shows TOVX's Change in Account Payables at -$397000.0 in Q1 2026, $209000.0 in Q4 2025, and $161000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 389,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 389,000.00 |
| Jun 30, 2026 | 389,000.00 |
| Mar 31, 2026 | -397,000.00 |
| Mar 31, 2026 | -397,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Mar 31, 2025 | -440,000.00 |
| Mar 31, 2025 | -440,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | -200,000.00 |
| Sep 30, 2024 | -200,000.00 |
| Jun 30, 2024 | 369,000.00 |
| Jun 30, 2024 | 369,000.00 |
| Mar 31, 2024 | -190,000.00 |
| Mar 31, 2024 | -190,000.00 |